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Absract 
The current study was conducted at the Center for Diabetes and Endocrinology of the Health Directorate in Thi- 
Qar province, during the period from October 2013 to May 2014. The study aimed and evaluate immune status 
of diabetes type I patients by measuring the levels of interleukins (IL-2, IL-12) in the serum using a technique 
enzyme-linked immune sorbent adsorptive  (ELISA),the study included a total of 72 patients with type I diabetes 
(37 males) and (35 females) and  there aged between 1-40 years.  When compared with 12 healthy control  
people.. The results showed a significant increase (P ≤ 0.01) in the levels of interleukins in the serum (IL-2, IL-
12) in all patients with type I diabetes compared to the control group. 
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Introduction                                                                                                            
Diabetes mellitus type 1 (also known as type 1 diabetes or T1DM ,formerly insulin dependent diabetes mellitus 
(IDDM) , or juvenile diabetes [1 , 2]. T1DM  is a chronic systemic metabolic disorders characterized by 
increased levels of glucose in the blood (hyperglycemia) and abnormalities in the metabolism of protein [3] , that 
results from  the autoimmune destruction of insulin-producing pancreatic beta  cells [4 , 5], by autoreactive T-
lymphocyte [6] , and that leading deficiency of insulin [7] , and this disease was once thought to be mediated 
exclusively by CD4_ T cells and is now recognized as one in which autoreactive CD8_ T cells play a 
fundamental pathogenic role [8] . The etiology of T1D is complex and involves both genetic and environmental 
factors which play important roles [9 ,10 ,11] . A permissive genetic background is required for the development 
of the islet autoimmune process generating antibodies (Ab) against insulin insulin auto antibodies  (IAA), 
glutamic acid decarboxylase isoform 65 (GADA65-Ab), and protein tyrosine phosphatase (IA2) [12 , 13] . 
The incidence of T1DM is reported to be increasing by 3-5% per year, and the number of people with 
diabetes is estimated to reach 380 million by 2025 [14]. The incidence rate of childhood T1DM is increasing 
dramatically in many countries over the past 20 years [15] .The classical symptoms of type 1 diabetes include 
polyuria (frequent urination),polydipsia (increased thirst),  Xerostomia  (dry mouth), polyphagia (increased 
hunger), fatigue, and weight loss [16 ,17] . 
The diabetic complications are divided into microvascular (nephropathy, retinopathy, and neuropathy) 
and macrovascular (cardiovascular) disease. Once considered a part of type 1 diabetes itself, the observation that 
similar complications also arise in patients with secondary diabetes led to the view that complications are caused 
by the hyperglycaemic milieu. The blood glucose values that define diabetes itself are set by the risk of diabetic 
microvascular complications  [18,  19] . 
 
Cytokines:  
Cytokines are central mediators of inflammation by controlling innate and adaptive immune responses as well as 
tissue damage, defense, repair, and remodeling. Type 1 diabetes is an inflammatory disease of the pancreatic 
islet, in which insulin-producing β-cells are preferentially destroyed to varying degrees by the concerted action 
of autoreactive T-cells and monocytic cells [20] .  The physiological response  to physical exercise includes 
secretion of pro- and anti-inflammatory cytokines, counterregulatory hormones, and growth factors  [21,22]. All 
elements of this complex response pattern are relevant to children with type 1 diabetes (T1DM) [23] . 
 
Interleukin-2(IL-2): 
IL-2 is a 15 kDa 4-bundled α-helical protein mainly produced by activated CD4+ T lymphocytes. However, the 
expression of IL-2 by naive CD8+ T cells, dendritic cells, and thymic cells has also been reported  [24,25] . The 
magnitude and duration of the T cell immune response is dependent on the interaction of IL-2 with its high-
affinity IL-2 receptor (IL-2R) which is composed of α, β and γ subunits. The intermediate affinity IL-2R is 
composed of IL-2Rβ (CD122) and IL-2Rγ (CD132) and is constitutively expressed on resting T lymphocytes. 
However, IL-2Rα (CD25) is only induced after T-cell activation, which allows the formation of the high-affinity 
IL-2R[26]. IL-2 have been identified as contributors to the breakdown of central and/or peripheral tolerance, 
although the precise mechanisms associated with pathogenesis remain to be defined [27,28,29,30,31,32] . 
Circumstantial evidence suggests that regulatory T cells (T-regs cells) control the progression of 
diabetes. Disruption of  T-reg cell development and homeostasis by blocking of the CD28-B7pathway or IL-2 
activity in NOD mice leads to acceleration of diabetes [33,34]. 
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Interleukin  -12 (IL-12) : 
Interleukin-12 is a cytokine produced by antigen presenting cells like Dendritic Cells (DC), macrophages also by 
NK cells. It plays a critical role in cell mediated immunity. It affects a variety of stages in the immune response; 
it prompts NK cells and T cells to produce pro-inflammatory cytokines, such as IFN- , IL-2, IL-3 and TNF- ; it 
contributes to NK cell maturation [35] ; and, along with other pro-inflammatory factors, it stimulates 
CD4+CD25- T cell activation in the presence of regulatory T cells [36].  Interleukin-12 also regulates naive T 
cell differentiation into T helper type 1 lymphocytes (Th1), and inhibits differentiation into T helper type 2 
lymphocytes (Th2) [37]. It has been documented that increased systemic inflammatory activity in patients with 
coronary artery disease is associated with a prominent Th1 response [38]. Current data suggest that IL-12 plays a 
critical role in the pathogenesis of T1DM [39] .      
The significance of IL-12 in human autoimmunity is not clear, and serum levels of IL-12 in diabetes 
mellitus have not been well established. Elevated levels of this cytokine have been observed in most autoimmune 
diseases [40,41]. 
IL-12 is a disulfide linked heterodimer composed of a heavy chain of 40 kDa (p40) and a light chain of 
35 kDa (p35). The two subunits of IL-12 are in contrast to most cytokines, which possess only one polypeptide 
chain. Many cell types express the p35 chain, while the p40 subunit is expressed mainly by activated 
macrophages and B cells  [42] . 
 
Materials & methods  
study desigen :  
This study was performed  on (72) Iraqi patients with T1DM patients, who attended the consultant clinic for 
Type 1 diabetes mellitus in endocrine and diabetic center in Al-Nasiriya city in the period from beginning 
October  2013 to  end May   2014. This study included too (12) person  apparently healthy individuals as a 
control group. , who have no history or clinical evidence of T1DM or any other chronic disease, and no obvious 
abnormalities . 
Blood Samples Collection:  
Blood samples were collected by venipuncture from 100 patients and30 controls (five milliliters of venous blood) 
were drawn by  disposable syringe under aseptic technique. were placed in a sterile plane tube and allowed to 
clot, then serum was separated by centrifugation at 4000 rpm  for 15 minutes. The serum was stored at -10 C˚ . 
These  sera (72  T1DM patients and  12 controls) were used for estimating the concentration   of interleukin  (IL- 
2 , and IL-12) . 
Methods  
Kit of (IL-2&IL-12) provided by CUSABIO company . The sera of patients and controls were assessed for the 
level of tow cytokines ,which were  IL-2 , IL-12, by means of ELISA that were based on similar principles . 
A - Principles of Assay :  
This assay employs the quantitative sandwich enzyme immunoassay technique. Antibody specific for IL-2 , IL-
12 has been pre-coated onto a micro plate. Standards and samples are pipetted into the wells and any IL-2,IL-12 
present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated 
antibody specific for IL-2,IL-12 is added to the wells. After washing, avidin conjugated Horseradish Peroxidase 
(HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate 
solution is added to the wells and color develops in proportion to the amount of IL-2,IL-12 bound in the initial 
step. The color development is stopped and the intensity of the color is measured . 
B – Assay procedure : 
Bring all reagents and samples to room temperature before use. Centrifuge the sample again after thawing before 
the assay. It is recommended that all samples and standards be assayed in duplicate. 
1. Prepare all reagents, working standards, and samples as directed in the previous sections. 
2. Refer to the Assay Layout Sheet to determine the number of wells to be used and put any remaining wells and 
the desiccant back into the pouch and seal the ziploc, store unused wells at 4°C. 
3. Add 100µl of standard and sample per well. Cover with the adhesive strip provided. Incubate for 2 hours at 
37°C. A plate layout is provided to record standards and samples assayed. 
4. Remove the liquid of each well, don’t wash. 
5. Add 100µl of Biotin-antibody (1x) to each well. Cover with a new adhesive strip. Incubate for 1 hour at 37°C. 
(Biotin-antibody (1x) may appear cloudy. Warm up to room temperature and mix gently until solution appears 
uniform.) 
6. Aspirate each well and wash, repeating the process two times for a total of three washes. Wash by filling each 
well with Wash Buffer (200µl) using a squirt bottle, multi-channel pipette, manifold dispenser, or autowasher, 
and let it stand for 2 minutes, complete removal of liquid at each step is essential to good performance. After the 
last wash, remove any remaining wash Buffer by aspirating ordecanting. Invert the plate and blot it against clean 
paper towels. 
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7. Add 100µl of HRP-avidin (1x) to each well. Cover the microtiter plate with a new adhesive strip. Incubate for 
1 hour at 37°C. 
8. Repeat the aspiration/wash process for five times as in step 6. 
9. Add 90µl of TMB Substrate to each well. Incubate for 15-30 minutes at 37°C. Protect from light. 
10. Add 50µl of Stop Solution to each well, gently tap the plate to ensure thorough mixing. 
11. Determine the optical density of each well within 5 minutes, using a microplate reader set to 450 nm. If 
wavelength correction is available, set to 540 nm or 570 nm. Subtract readings at 540 nm or 570 nm from the 
readings at 450 nm. This subtraction will correct for optical imperfections in the plate. Readings made directly at 
450 nm without correction may behigher and less accurate. 
 
Statistical analysis  
The analysis of data were expressed as mean ± SD. The comparisons between each T1DM patients group with  
matched healthy control were performed with T-test  by using computerized Minitab 14 program. P<0.01 was 
considered to be the least limit of significance, the statistical analysis were done by using Pentium-4 computer 
through the ( SPSS program) Statistical Package For Social Sciences (version-20).                                        
 
Results  
The present study showed the presence of a significant increase (P ≤ 0.05) in the rate of concentrations of  IL-12, 
IL-2 in sera of  patients with type I diabetes, compared with the average concentration in the sera of healthy 
control group  , as was the rate of concentration of  IL-2 in patients (39.099pg / ml) compared to the control 
group (19.623pg/ml) with significant difference (0.01), while IL-12 concentration    (60.154 pg / ml) for patients  
compared to the healthy  control (29.417 pg / ml ) with a significant difference (0.01) .  
Table (1) Comparison of serum (IL-2,IL-12) concentrations (pg/dL)  of the patient groups  with healthy 
controls group .                                                  
Parameter Subject No of cases Mean   ± SD T-value Df P-value 
IL – 2 
Pateints 70 39.099 ± 25.900 
2.530 80 0.01 
Control 12 19.623 ± 14.322 
IL – 12 
Pateints 70 60.154 ± 39.477 2.622 
 
 
80 
0.01 
Control 12 29.417 ± 21.445 
HS= Highly Significant difference (P<0.001).     NS= Non Significant difference (P>0.05). 
df : degree freedom 
Discussion 
The results of the current study showed a high level of concentration of IL-12 in the patient group compared to 
the healthy  control group and a significant difference (p ≤ 0.01) for patients (60.154 ± 39.477) and the healthy 
control group (29.417 ± 21.445)                      .                                                                   
These results agree with the results studies of all [35,39.43], whose  indicated to a increase in the 
concentration of IL-12 in the sera of patients with type I diabetes. The increase of IL-12 in most autoimmune 
diseases such as multiple sclerosis [44], as well as events in arthritis and psoriasis[45].                
The elevated serum IL-12 levels in T1DM were related to the excessive pro-insulin secretion. 
Therefore, this cytokine may play a critical role in the pathogenesis of T1DM, since IL-12 is important in 
immune response to infections. It has been shown that in the absence of infection, IL-12 induced auto-reactive T 
cell responses might predispose to self-destructive immunity but the significance of IL-12 changes in the blood 
of patients with T1DM remains unclear. The IL-12 accelerates the development of macrovascular complications 
in the disease [46]. Additionally, it has been noted that elevated glucose levels in diabetic animals stimulates 
inflammatory reactions related to IL-12 cytokine gene expression [47] .                                                                                      
However, it is not known whether factors related to the course of T1DM , such as metabolic 
compensation, beta cell secretory dysfunction and insulin resistance  affect IL-12 concentrations, but in a recent 
study, a multiple regression analysis revealed that the IL-12 serum level in T1DM primarily was dependent  
upon fasting pro-insulin concentration [43] . It has been suggested that cytokines released by 
monocytes/macrophages, including IL- 1beta, IL-12  could have an initial role in islet β-cell damage [35] . Pro-
inflammatory cytokines may be increased by hyperglycemia in subjects with impaired glucose tolerance, this 
result was confirmed, because all diabetics had elevated serum level of IL12. This cytokine may be useful 
biomarker for early detection of diabetes[48] . 
The IL-2 Tests showed the results of the current study, the increase in the level concentration of IL-2 
in the patient group (39.099 ± 25.900) compared to the healthy control group (14.322 19.623 ±) and a significant 
difference (P ≤ 0.01)  . Type I diabetes is a chronic inflammatory disease, some's  researches  indicated  the 
cytokines increase when the injury chronic inflammatory diseases and malignant diseases [49,50,51,52,53,54] . 
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The results of this study are agree with the results of a study [55] , whose have indicated the high level of 
concentration of IL-2 in the sera of patients with type I diabetes           .                          
The reason for the increase in the concentration of IL-2 is associated with elevated concentration of IL-
12 as the IL-12 released from APCs activates TH1-type CD4+ T cells, causing the immune balance between 
effector and regulatory cells to breakdown. TH1 cells produce IL-2, which activates b cell–specific pre-cytotoxic 
T cells (Pre CTL) to become cytotoxic (CTL), and IFN-g, which may cause macrophages (MØ) to become 
cytotoxic. These cytotoxic macrophages release b cell–cytotoxic cytokines including IL-1b, TNF-a, and IFN-g, 
and free radicals. TH1 cells also secrete cytokines that are directly cytotoxic to b cells. b Cell antigen specific 
CD8+ cytotoxic T cells (CTL) recognize antigens expressed on b cells in association with MHC class I 
molecules. These CTLs release granzyme and perforin (cytolysin), which are toxic to b cells. In addition, Fas- 
and TNFR-mediated apoptosis are involved in b cell destruction. In this way ,macrophages , T cells, and 
cytokines synergistically act to destroy b cells, resulting in the development of autoimmune type 1 diabetes 
[56]                        . 
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